Li Wei, Cui Heng, Meng Fan-Qiang, Chang Xiao-Hong, Zhang Guo, Liu Bei, Li Zi-Hai
Gynecologic Oncology Center, Peking University People's Hospital, 11 Xi Zhi Men South Street, Xi Cheng District, Beijing, China.
Cancer Immunol Immunother. 2008 Feb;57(2):143-54. doi: 10.1007/s00262-007-0354-8. Epub 2007 Jul 6.
Anti-idiotype (Id) antibodies can be used to induce specific cellular immune responses against tumor antigens, but the mechanism of antigenicity is not always clear. We previously reported an anti-Id antibody, 6B11, which mimics human ovarian cancer associated antigen OC166-9. To explore the molecular basis of cellular immune response induced by 6B11, a panel of peptides derived from complementarity determining region (CDR) of 6B11 were synthesized. After a series of immunologic experiments, we found that the light chain CDR3 peptide and heavy chain CDR3 peptide were the MHC class I and class II epitopes of 6B11, respectively. The combination of MHC class I and class II epitopes is more effective than 6B11 in inducing specific cellular immune response against ovarian cancer. Our study provided the structural basis of antigenicity of 6B11. The identification of antigen-specific T cell eptitopes in 6B11 should facilitate the design of epitope-based vaccine against human ovarian cancer.
抗独特型(Id)抗体可用于诱导针对肿瘤抗原的特异性细胞免疫反应,但其抗原性机制并不总是清晰的。我们之前报道了一种抗Id抗体6B11,它模拟人卵巢癌相关抗原OC166 - 9。为了探究6B11诱导细胞免疫反应的分子基础,合成了一组源自6B11互补决定区(CDR)的肽段。经过一系列免疫学实验,我们发现轻链CDR3肽段和重链CDR3肽段分别为6B11的MHC I类和II类表位。MHC I类和II类表位的组合在诱导针对卵巢癌的特异性细胞免疫反应方面比6B11更有效。我们的研究提供了6B11抗原性的结构基础。6B11中抗原特异性T细胞表位的鉴定应有助于设计基于表位的人卵巢癌疫苗。